Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Disclosure under Rule 2.10(c)

17th Oct 2018 07:00

RNS Number : 2661E
Sinclair Pharma PLC
17 October 2018
 

Toscafund Asset Management LLP

Disclosure under Rule 2.10(c) of The City Code on Takeovers and Mergers

 

 

Toscafund Asset Management LLP ("Toscafund") provided a non-binding letter of intent to Huadong Medicine Aesthetics Investment (Hong Kong) Limited on 28 August 2018 regarding the proposed acquisition of Sinclair Pharma plc as referred to in the announcement of the recommended cash offer on 18 September 2018.

 

The non-binding letter of intent was for 148,613,603 ordinary shares of 1p each in Sinclair Pharma plc.

 

In accordance with Rule 2.10(c) of The City Code on Takeovers and Mergers it is today confirmed that following a disposal Toscafund no longer intends to comply with the letter of intent in respect of 92,000,000 ordinary shares of 1p each in Sinclair Pharma plc. The non-binding letter of intent issued on 28 August 2018 still applies to 56,613,603 ordinary shares of 1p each in Sinclair Pharma plc.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCGGGWCUUPRGRQ

Related Shares:

Sinclair Pharma
FTSE 100 Latest
Value8,809.74
Change53.53